Sponsors (4)
The bill makes it easier for generics and biosimilars to obtain approval and reach the market for non‑patented uses—likely lowering drug costs for many—but does so by reducing certain patent enforcement tools and introducing legal uncertainty (including retroactive effects and ambiguous promotional boundaries).
Patients with chronic conditions and taxpayers gain greater access to lower‑cost generic and biosimilar options for indications not covered by patents, likely lowering drug prices and out‑of‑pocket costs.
Generic and biosimilar manufacturers (including small businesses) and hospitals/health systems can seek FDA approval and bring products to market for non‑patented uses without facing method‑of‑use infringement liability.
Hospitals, health systems, and manufacturers benefit from clearer legal definitions and scope for courts and industry, reducing some litigation uncertainty around method‑of‑use claims and regulatory submissions.
Patent owners and pharmaceutical companies lose enforcement leverage against off‑label promotion tied to method‑of‑use patents, which may reduce incentives to seek method‑of‑use patents and could dampen investment in new indication research.
Retroactive application to pending and past conduct may upset parties who relied on earlier law or were previously sued, creating legal uncertainty and potential new liability for past actions.
Ambiguities about what counts as referencing a patented condition in labeling or promotion could spur new litigation over acceptable promotional language, increasing compliance costs and legal risk for hospitals, health systems, and manufacturers.
Based on analysis of 2 sections of legislative text.
Creates a statutory safe harbor allowing certain ANDA, 505(b)(2), and biosimilar activities to avoid method-of-use patent infringement if labeling and promotion omit patented uses.
Introduced January 9, 2025 by John Wright Hickenlooper · Last progress January 9, 2025
Creates a legal safe harbor so companies seeking FDA approval for generic drugs, 505(b)(2) drugs, and biosimilars can submit applications, seek approval, market, or describe their products without being treated as infringing certain method-of-use patents, as long as their labeling, promotion, and marketing do not reference the patented uses. The law adds definitions for key terms, aligns the safe harbor with existing FDA labeling rules, and applies retroactively to past, present, and future conduct and litigation. The change aims to protect so-called “skinny labeling” and limited approvals from method-of-use patent suits while leaving intact requirements that applicants must not promote or label for patented conditions. It likely lowers some legal barriers for generic and biosimilar entry, may reduce certain patent litigation, and will affect brand drug patent holders, payers, health systems, and patients who may see increased competition and lower prices.